Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SKB264 versus investigator's choice chemotherapy as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer
CTR20240413Phase 3Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC), sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Feb 2024; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20240413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240413.